Psychedelic Microdosing: Prevalence and Subjective Effects

被引:73
作者
Cameron, Lindsay P. [1 ]
Nazarian, Angela [2 ]
Olson, David E. [3 ,4 ,5 ]
机构
[1] Univ Calif Davis, Neurosci Grad Program, Davis, CA 95616 USA
[2] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA
[3] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA
[4] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA
[5] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA
关键词
Psychedelic; microdosing; depression; PTSD; anxiety; LSD; DISORDERS; PSILOCYBIN; BRAIN; DRUGS; ACTIVATION; ANXIETY; BURDEN; MTOR; COST;
D O I
10.1080/02791072.2020.1718250
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic compounds on a chronic, intermittent schedule - a practice known as psychedelic microdosing - is becoming increasingly popular among young adults due to its purported ability to reduce symptoms of depression and anxiety while improving cognitive function and promoting social interaction. Using an anonymous online survey, we collected data from 2347 people to 1) assess the prevalence of psychedelic microdosing and characterize the demographics of microdosers, 2) determine whether microdosers associate the practice with changes in mood, cognitive function, social interaction, or physiology, and 3) investigate frequent motives for discontinuing the practice. Fifty-nine percent of respondents (N-T = 2183) reported familiarity with the concept of psychedelic microdosing, with 17% (383 respondents, N-T = 2200) having engaged in this practice. Microdosers attributed psychedelic microdosing with improving their mood, decreasing their anxiety, and enhancing their memory, attention, and sociability. The most frequently cited reasons for quitting microdosing (N-T = 243) were the risks associated with taking an illegal substance (24.28%) and the difficulty of obtaining psychedelic compounds (22.63%). Overall, our findings suggest that psychedelic microdosing is relatively common and is subjectively associated with a broad spectrum of socio-affective, cognitive, and physical outcomes.
引用
收藏
页码:113 / 122
页数:10
相关论文
共 50 条
  • [1] Psychedelic microdosing benefits and challenges: an empirical codebook
    Anderson, Thomas
    Petranker, Rotem
    Christopher, Adam
    Rosenbaum, Daniel
    Weissman, Cory
    Dinh-Williams, Le-Anh
    Hui, Katrina
    Hapke, Emma
    [J]. HARM REDUCTION JOURNAL, 2019, 16 (1)
  • [2] Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
    Anderson, Thomas
    Petranker, Rotem
    Rosenbaum, Daniel
    Weissman, Cory R.
    Dinh-Williams, Le-Anh
    Hui, Katrina
    Hapke, Emma
    Farb, Norman A. S.
    [J]. PSYCHOPHARMACOLOGY, 2019, 236 (02) : 731 - 740
  • [3] Cost of disorders of the brain in Europe
    Andlin-Sobocki, P
    Jönsson, B
    Wittchen, HU
    Olesen, J
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 1 - +
  • [4] [Anonymous], AR YOU AM MIDDL CLAS
  • [5] Activation of mTOR: a culprit of Alzheimer's disease?
    Cai, Zhiyou
    Chen, Guanghui
    He, Wenbo
    Xiao, Ming
    Yan, Liang-Jun
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1015 - 1030
  • [6] Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents
    Cameron, Lindsay P.
    Benson, Charlie J.
    DeFelice, Brian C.
    Fiehn, Oliver
    Olson, David E.
    [J]. ACS CHEMICAL NEUROSCIENCE, 2019, 10 (07): : 3261 - 3270
  • [7] Dark Classics in Chemical Neuroscience: N,N-Dimethyltryptamine (DMT)
    Cameron, Lindsay P.
    Olson, David E.
    [J]. ACS CHEMICAL NEUROSCIENCE, 2018, 9 (10): : 2344 - 2357
  • [8] Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
    Cameron, Lindsay P.
    Benson, Charlie J.
    Dunlap, Lee E.
    Olson, David E.
    [J]. ACS CHEMICAL NEUROSCIENCE, 2018, 9 (07): : 1582 - 1590
  • [9] Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
    Carhart-Harris, Robin L.
    Roseman, Leor
    Bolstridge, Mark
    Demetriou, Lysia
    Pannekoek, J. Nienke
    Wall, Matthew B.
    Tanner, Mark
    Kaelen, Mendel
    McGonigle, John
    Murphy, Kevin
    Leech, Robert
    Curran, H. Valerie
    Nutt, David J.
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [10] The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
    Carhart-Harris, Robin L.
    Goodwin, Guy M.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2017, 42 (11) : 2105 - 2113